CMC Ambroise Paré Hartmann
Neuilly-sur-Seine, 92200, France
Location status: Recruiting
Location contact
Jean-François LLORY, M.D.
SUB_INVESTIGATOR
Jean-Michel VANNETZEL, M.D.
PRINCIPAL_INVESTIGATOR
Marie-Laure CHABI, M.D.
SUB_INVESTIGATOR
NCT Number: NCT06807502
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.
The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
Neuilly-sur-Seine, 92200, France
Location status: Recruiting
Jean-François LLORY, M.D.
SUB_INVESTIGATOR
Jean-Michel VANNETZEL, M.D.
PRINCIPAL_INVESTIGATOR
Marie-Laure CHABI, M.D.
SUB_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For all participants :
For participants with metastatic breast cancer:
For participants with non-metastatic invasive breast cancer:
For healthy volunteers:
Exclusion criteria
For all participants:
For healthy volunteers:
The product is not used directly on the subject, but on a blood sample taken from the participant.
Time frame: From enrollement to the end of follow up at 9 months
Evolution of the number of CTC isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients. Average number of CTCs measured during the study (D0, W6, W12, W24, W36) with a tolerance of +/- 8 days for the visits
Time frame: From enrollement to the end of follow up at 9 months
Analysis of the expression of specific antigens and the presence of informative mutations on CTCs isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients during the study (D0, W6, W12, W24, W36)
Contact information is provided by the study sponsor or research team.
Jessica GROULT, Ph.D
CONTACT
Sina NASERIAN, Ph.D
CONTACT
ScreenCell
Industry
Acronym: PROBE-CTC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03427450
Breast Cancer, Metastatic, Breast Diseases
Los Angeles, California, United States
View Trial DetailsNCT07007559
Breast Cancer, Metastatic, Breast Diseases
Tucson, Arizona, United States
View Trial DetailsNCT06762483
Breast Cancer, Metastatic, Breast Diseases
Milan, Italy
View Trial DetailsNCT05835570
Breast Cancer, Metastatic, Breast Diseases
Wuhan, Hubei, China
View Trial Details